Hip & pelvis

The Korean Hip Society (대한고관절학회)
권호 표지
DOI QR코드

DOI QR Code

Management of Osteoporosis Medication after Osteoporotic Fracture

  • Young Kwang Oh (Department of Orthopaedic Surgery, Pusan National University Yangsan Hospital, Pusan National University School of Medicine) ;
  • Nam Hoon Moon (Department of Orthopaedic Surgery, Pusan National University Hospital) ;
  • Won Chul Shin (Department of Orthopaedic Surgery, Pusan National University Yangsan Hospital, Pusan National University School of Medicine)
  • Received : 2022.04.18
  • Accepted : 2022.08.10
  • Published : 2022.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The aim of this study was to provide helpful information for use in selection of an appropriate medication after osteoporotic fractures through conduct of a literature review. In addition, a review of the recommendations of several societies for prevention of subsequent fractures was performed and the appropriate choice of medication for treatment of atypical femur fractures was examined. Clinical perspective was obtained and an updated search of literature was conducted across PubMed and MEDLINE and relevant articles were selected. The articles were selected manually according to relevance, and the references for identified articles and reviews were also evaluated for relevance. The following areas are reviewed: Commonly prescribed osteoporosis medications: BPs (bisphosphonates), denosumab, and SERMs (selective estrogen receptor modulators) in antiresorptive medications and recombinant human parathyroid hormone teriparatide, recently approved Romosuzumab in anabolic agents, clinical practice guidelines for the management of osteoporosis, osteoporotic fracture, and atypical femur fracture. Most medications for treatment of osteoporosis do not delay fracture healing and the positive effect of teriparatide on fracture healing has been confirmed. In cases where an osteoporotic fracture is diagnosed, risk assessment should be performed for selection of very high-risk patients in order to prevent subsequent fractures, and administration of anabolic agents is recommended.

Keywords

Acknowledgement

This study was supported by a 2022 research grant from Pusan National University Yangsan Hospital. We are grateful to the Springer Nature, Oxford University Press, and Elsevier for their permission to reuse figures.

References

  1. Roser M, Ortiz-Ospina E, Ritchie H. Life expectancy [Internet]. Our World in Data; 2013 [updated 2019 Oct; cited 2022 Mar 1]. Available from: https://ourworldindata.org/life-expectancy.
  2. Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992;2:285-9. https://doi.org/10.1007/BF01623184
  3. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15:721-39. https://doi.org/10.1359/jbmr.2000.15.4.721
  4. van Geel TA, van Helden S, Geusens PP, Winkens B, Dinant GJ. Clinical subsequent fractures cluster in time after first fractures. Ann Rheum Dis. 2009;68:99-102. https://doi.org/10.1136/ard.2008.092775
  5. Smith DP, Enderson BL, Maull KI. Trauma in the elderly: determinants of outcome. South Med J. 1990;83:171-7. https://doi.org/10.1097/00007611-199002000-00010
  6. von Ruden C, Augat P. Failure of fracture fixation in osteoporotic bone. Injury. 2016;47 Suppl 2:S3-10. https://doi.org/10.1016/S0020-1383(16)47002-6
  7. Cheung WH, Miclau T, Chow SK, Yang FF, Alt V. Fracture healing in osteoporotic bone. Injury. 2016;47 Suppl 2:S21-6. https://doi.org/10.1016/S0020-1383(16)47004-X
  8. Xue D, Li F, Chen G, Yan S, Pan Z. Do bisphosphonates affect bone healing? A meta-analysis of randomized controlled trials. J Orthop Surg Res. 2014;9:45. https://doi.org/10.1186/1749-799X-9-45
  9. Colon-Emeric C, Nordsletten L, Olson S, et al. Association between timing of zoledronic acid infusion and hip fracture healing. Osteoporos Int. 2011;22:2329-36. https://doi.org/10.1007/s00198-010-1473-1
  10. Duckworth AD, McQueen MM, Tuck CE, et al. Effect of alendronic acid on fracture healing: a multicenter randomized placebo-controlled trial. J Bone Miner Res. 2019;34:1025-32. https://doi.org/10.1002/jbmr.3679
  11. Cecilia D, Jodar E, Fernandez C, Resines C, Hawkins F. Effect of alendronate in elderly patients after low trauma hip fracture repair. Osteoporos Int. 2009;20:903-10. https://doi.org/10.1007/s00198-008-0767-z
  12. Rozental TD, Vazquez MA, Chacko AT, Ayogu N, Bouxsein ML. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. J Hand Surg Am. 2009;34:595-602. https://doi.org/10.1016/j.jhsa.2008.12.011
  13. Ha KY, Park KS, Kim SI, Kim YH. Does bisphosphonate-based anti-osteoporosis medication affect osteoporotic spinal fracture healing? Osteoporos Int. 2016;27:483-8. https://doi.org/10.1007/s00198-015-3243-6
  14. Peter B, Pioletti DP, Laib S, et al. Calcium phosphate drug delivery system: influence of local zoledronate release on bone implant osteointegration. Bone. 2005;36:52-60. https://doi.org/10.1016/j.bone.2004.10.004
  15. Aspenberg P. Bisphosphonates and implants: an overview. Acta Orthop. 2009;80:119-23. https://doi.org/10.1080/17453670902807466
  16. Tagil M, Annette W, Harding AK, Little D, Toksvig-Larsen S. Enhanced Pin fixation for un-coated standard pins by a single bisphosphonate infusion in hemicallotasis osteotomy. A double-blinded placebo controlled randomized study. Bone. 2008;42(Suppl 1):S87-8. https://doi.org/10.1016/j.bone.2007.12.165
  17. Friedl G, Radl R, Stihsen C, Rehak P, Aigner R, Windhager R. The effect of a single infusion of zoledronic acid on early implant migration in total hip arthroplasty. A randomized, double-blind, controlled trial. J Bone Joint Surg Am. 2009;91:274-81. https://doi.org/10.2106/JBJS.G.01193
  18. Dhert WJ, Thomsen P, Blomgren AK, Esposito M, Ericson LE, Verbout AJ. Integration of press-fit implants in cortical bone: a study on interface kinetics. J Biomed Mater Res. 1998;41:574-83. https://doi.org/10.1002/(sici)1097-4636(19980915)41:4<574::aid-jbm9>3.0.co;2-9
  19. Ganz R, Perren SM, Ruter A. [Mechanical induction of bone resorption]. Fortschr Kiefer Gesichtschir. 1975;19:45-8. German.
  20. Goldhahn J, Feron JM, Kanis J, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int. 2012;90:343-53. https://doi.org/10.1007/s00223-012-9587-4
  21. Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res. 2009;24:196-208. https://doi.org/10.1359/jbmr.081113
  22. Adami S, Libanati C, Adachi J, et al. Denosumab administration is not associated with fracture healing complications in postmenopausal women with osteoporosis: results from the FREEDOM trial. J Bone Miner Res. 2010;25(Suppl 1):MO0405. https://doi.org/10.1002/jbmr.5650251305
  23. Cao Y, Mori S, Mashiba T, et al. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res. 2002;17:2237-46. https://doi.org/10.1359/jbmr.2002.17.12.2237
  24. Spiro AS, Khadem S, Jeschke A, et al. The SERM raloxifene improves diaphyseal fracture healing in mice. J Bone Miner Metab. 2013;31:629-36. https://doi.org/10.1007/s00774-013-0461-x
  25. Andreassen TT, Ejersted C, Oxlund H. Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res. 1999;14:960-8. https://doi.org/10.1359/jbmr.1999.14.6.960
  26. Shibamoto A, Ogawa T, Duyck J, Vandamme K, Naert I, Sasaki K. Effect of high-frequency loading and parathyroid hormone administration on peri-implant bone healing and osseointegration. Int J Oral Sci. 2018;10:6. https://doi.org/10.1038/s41368-018-0009-y
  27. Aspenberg P, Genant HK, Johansson T, et al. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res. 2010;25:404-14. https://doi.org/10.1359/jbmr.090731
  28. Peichl P, Holzer LA, Maier R, Holzer G. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am. 2011;93:1583-7. https://doi.org/10.2106/JBJS.J.01379
  29. Huang TW, Chuang PY, Lin SJ, et al. Teriparatide improves fracture healing and early functional recovery in treatment of osteoporotic intertrochanteric fractures. Medicine (Baltimore). 2016;95:e3626. https://doi.org/10.1097/MD.0000000000003626
  30. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24:578-88. https://doi.org/10.1359/jbmr.081206
  31. Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res. 2010;25:2412-8. https://doi.org/10.1002/jbmr.135
  32. Schemitsch EH, Miclau T, Karachalios T, et al. Placebo-controlled study of romosozumab for the treatment of hip fractures. J Bone Joint Surg Am. 2020;102:693-702. https://doi.org/10.2106/JBJS.19.00790
  33. Bhandari M, Schemitsch EH, Karachalios T, et al. Romosozumab in skeletally mature adults with a fresh unilateral tibial diaphyseal fracture: a randomized phase-2 study. J Bone Joint Surg Am. 2020;102:1416-26. https://doi.org/10.2106/JBJS.19.01008
  34. Kim TY, Ha YC, Kang BJ, Lee YK, Koo KH. Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? J Bone Joint Surg Br. 2012;94:956-60. https://doi.org/10.1302/0301-620X.94B7.29079
  35. Amanat N, McDonald M, Godfrey C, Bilston L, Little D. Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair. J Bone Miner Res. 2007;22:867-76. https://doi.org/10.1359/jbmr.070318
  36. Hagino H, Sugimoto T, Tanaka S, et al. A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial05. Osteoporos Int. 2021;32:2301-11. Erratum in: Osteoporos Int. 2021;32:2143. https://doi.org/10.1007/s00198-021-05996-2
  37. Kanis JA, Burlet N, Cooper C, et al.;European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19:399-428. Erratum in: Osteoporos Int. 2008;19:1103-4. https://doi.org/10.1007/s00198-008-0560-z
  38. Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30:3-44. Erratum in: Osteoporos Int. 2020;31:209. Erratum in: Osteoporos Int. 2020;31:801. https://doi.org/10.1007/s00198-018-4704-5
  39. Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int. 2020;31:1-12. Erratum in: Osteoporos Int. 2020;31:797-8. https://doi.org/10.1007/s00198-019-05176-3
  40. Altintas, F, Ozkut AT, Beyzadeoglu T, Eren A, Guven M. [The effect of risedronate treatment on bone turnover markers in patients with hip fracture]. Acta Orthop Traumatol Turc. 2007;41:132-5. Turkish.
  41. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-809. https://doi.org/10.1056/NEJMoa074941
  42. Kim K, Won YY, Lee SW, Seo KD. The effect of teriparatide on the hip: a literature review. Hip Pelvis. 2021;33:45-52. https://doi.org/10.5371/hp.2021.33.2.45
  43. Kim SJ, Park HS, Lee DW, Lee JW. Short-term daily teriparatide improve postoperative functional outcome and fracture healing in unstable intertrochanteric fractures. Injury. 2019;50:1364-70. https://doi.org/10.1016/j.injury.2019.06.002
  44. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society guideline update. J Clin Endocrinol Metab. 2020;105:dgaa048. https://doi.org/10.1210/clinem/dgaa048
  45. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 update. Endocr Pract. 2020;26(Suppl 1):1-46. https://doi.org/10.4158/GL-2020-0524SUPPL
  46. Miyakoshi N, Aizawa T, Sasaki S, et al. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. J Bone Miner Metab. 2015;33:553-9. https://doi.org/10.1007/s00774-014-0617-3
  47. Saleh A, Hegde VV, Potty AG, Schneider R, Cornell CN, Lane JM. Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. HSS J. 2012;8:103-10. https://doi.org/10.1007/s11420-012-9275-y
  48. Shi Z, Zhou H, Pan B, et al. Effectiveness of teriparatide on fracture healing: a systematic review and meta-analysis. PLoS One. 2016;11:e0168691. https://doi.org/10.1371/journal.pone.0168691
  49. van de Laarschot DM, McKenna MJ, Abrahamsen B, et al. Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European Calcified Tissue Society. J Clin Endocrinol Metab. 2020;105:1682-99. https://doi.org/10.1210/clinem/dgz295
  50. Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Stopping denosumab. Curr Osteoporos Rep. 2019;17:8-15. Erratum in: Curr Osteoporos Rep. 2020 Jan 31. https://doi.org/10.1007/s11914-020-00565-8
  51. Anastasilakis AD, Makras P, Yavropoulou MP, Tabacco G, Naciu AM, Palermo A. Denosumab discontinuation and the rebound phenomenon: a narrative review. J Clin Med. 2021;10:152. https://doi.org/10.3390/jcm10010152